uploads/37150_HorizonPrizeGradient2.jpg
Presented with
uploads/37135_Horizon_Logo_Full_Color_RGB.png

How can technology help people with rare diseases get the right care faster and more accurately?

The Horizon Prize: 2021

Closed

Submissions are closed

Timeline

  • Applications Open

    March 24, 2021 7:45am EDT
  • Solution Deadline

    March 24, 2021 12:00pm EDT
  • Challenge Opens

    March 24, 2021 12:00pm EDT
  • Extended Deadline: 12pm EDT

    June 21, 2021 12:15pm EDT
  • Finalist Selection

    August 13, 2021 11:00am EDT
  • Finalist Interviews

    September 14, 2021 11:59pm EDT
  • Pitch Event

    September 20, 2021 12:00pm EDT

Challenge Overview

Today, there are more than 7,000 rare diseases affecting over 400 million people worldwide. People who have a rare disease often find themselves misunderstood and underserved by health care systems. An estimated four in ten patients with rare disease experience initial misdiagnoses–often resulting in unnecessary harm, frustration, expense, and disease progression. Some estimates indicate these patients may wait nearly five years and see an average of seven different health care providers before their condition is accurately diagnosed.

Technology can be a powerful tool to unlock improved pathways for rare disease patients. Telemedicine can speed up connections to specialists such as genetic counselors and oncologists. Advanced analytics can identify patterns in misdiagnosis and guide better decision making. And patient-centered innovations can promote community and agency among rare disease patients.

The Horizon Prize, powered by MIT Solve, seeks technology-based solutions that use data to help rare disease patients get the right care faster and more accurately. To that end, this Challenge seeks solutions that:

  • Leverage big data and analytics to improve the detection and diagnosis of rare diseases

  • Address the unjust and disproportionate burden of rare diseases faced by disinvested communities and historically underrepresented identity groups

  • Promote community and connection among rare disease patients and their advocates

  • Unlock collaboration among patients, scientists, and health care providers to improve patient outcomes

Eligibility

Up to $150,000 in prize funding is available for up to two solution teams selected for The Horizon Prize. 

Finalists will be invited to pitch their solutions to a panel of distinguished judges in September 2021. 

The Horizon Prize encourages and actively seeks solutions led by people with rare diseases and from underrepresented groups and identities. 

Judging Criteria

Solutions will be evaluated based on the following criteria:

Alignment: Solution uses data, digital tools and/or analytics to identify rare diseases, promote collaboration and community response to rare diseases, or strengthen collaboration capabilities between patients, providers, and scientists.

Potential for Impact: Solution has a reasonable and measurable plan to impact the lives of patients, healthcare providers, researchers, or community members impacted by or working with rare diseases.

Feasibility: Solution implementation is feasible, and the team has a reasonable plan for operational sustainability and measurable results that can be proven to work.

Innovative Approach: Solution includes a new technology or a new application of technology; a business/policy model, process, or cross-sectorial approach that relies on technology to be successful.

Scalability: Solution can be equitably scaled to improve the lives of more people, across geographical, sociocultural, or sectorial borders.

Inclusive Human-Centered Design: Solution is designed with and for underserved communities; the solution team demonstrates proximity to the community, and embodies and addresses diversity, equity, and inclusion through their solution.

Judging Criteria

  • Alignment: Solution uses data, digital tools and/or analytics to identify rare diseases, promote collaboration and community response to rare diseases, or strengthen collaboration capabilities between patients, providers, and scientists.
  • Potential for Impact: Solution has a reasonable and measurable plan to impact the lives of patients, healthcare providers, researchers, or community members impacted by or working with rare diseases.
  • Feasibility: Solution implementation is feasible, and the team has a reasonable plan for operational sustainability and measurable results that can be proven to work.
  • Innovative Approach: Solution includes a new technology or a new application of technology; a business/policy model, process, or cross-sectorial approach that relies on technology to be successful.
  • Scalability: Solution can be equitably scaled to improve the lives of more people, across geographical, sociocultural, or sectorial borders.
  • Inclusive Human-Centered Design: Solution is designed with and for underserved communities; the solution team demonstrates proximity to the community, and embodies and addresses diversity, equity, and inclusion through their solution.

Solutions

Selected

Congenica

By Sandro Morganella
Sandro Morganella Nicolas Bryant Peter Fox Bob Vaughan Nick Lench
Selected

ThinkGenetic, Inc.

By David Jacob
David Jacob Len Barker
Finalist

Research to the People

By Emily Wang
Emily Wang John M Peter Kane Fereshteh Kenari Jahaniani Michael Snyder
Finalist

Elsa Health

By Ally Salim
Ally Salim Megan Allen
Finalist

MDA MOVR Data Hub

By Marissa Lozano
Marissa Lozano Rayne Rodgers Sharon Hesterlee
Submitted

Sehat Kahani (Story of Health)

By Iffat Zafar
Iffat Zafar
Submitted

patient education X-PLAIN

By kleopatra Alamantariotou
kleopatra Alamantariotou Moe A. Ajam
Submitted

InstaSerum

By Sushmitha Thirumalaivasan
Sushmitha Thirumalaivasan Shruti Srinivas Brindhi  Amalraj
Submitted

Gen Breast Epic Center

By Juan Sanjuan
Juan Sanjuan Justo German Olaya R.
Submitted

Digital Services for autoimmune patients

By Saad Hasan
Saad Hasan
Submitted

Denotia

By Vishnu Sampathkumar
Vishnu Sampathkumar Naman Modani Aranyo Ray Ngan Ho Anaya Gupta
Submitted

Confika

By Tetevi Ekon
Tetevi Ekon
Submitted

Arqcare

By Joseph Mulabbi
Joseph Mulabbi Refu Connect George Mwangi Mula Joe
Submitted

UCLA

By Manish Butte
Manish Butte
Submitted

Strabi-Cure

By Suha Zubair
Suha Zubair Zain Samdani Asfia Jabeen Zubair Abdur Rahman

Judges

Samuel Agyei Wiafe

Samuel Agyei Wiafe

Rare Disease Ghana Initiative, Founder and Executive Director
Miles Sandler

Miles Sandler

Ewing Marion Kauffman Foundation, Director of Education-Engagement
Donna Cryer

Donna Cryer

Global Liver Institute, Founder and CEO
Ritu  Jain

Ritu Jain

President of DEBRA Singapore and Director of RDI, APARDO & DEBRA International
Natasha 	 Bonhomme

Natasha Bonhomme

Genetic Alliance, Chief Strategy Officer